Blocking Hrd1 Protein Shields the Heart from Ischemia-Reperfusion Damage
A new molecular target — the E3 ubiquitin ligase Hrd1 — may prevent heart damage after blood flow is restored following a heart attack.
Summary
When a blocked coronary artery is reopened, the returning blood flow paradoxically damages heart tissue — a process called ischemia-reperfusion (I/R) injury. Researchers at Fudan University identified a protein called Hrd1 that spikes in heart blood vessel cells during this injury. Hrd1 tags another protective protein, ALDH2, for degradation, preventing it from forming its active shape and disrupting a key signaling pathway that keeps blood vessels healthy. Mice engineered to lack Hrd1 in endothelial cells had significantly less heart damage, inflammation, and vessel dysfunction after I/R injury. Importantly, a drug that blocks Hrd1 also reduced injury in animal models, suggesting this pathway could be targeted therapeutically to protect patients undergoing procedures like angioplasty or cardiac surgery.
Detailed Summary
Myocardial ischemia-reperfusion (I/R) injury — the paradoxical tissue damage that occurs when blood flow is restored to a blocked heart artery — remains one of cardiology's most vexing unsolved problems. Despite advances in reperfusion therapy, a significant portion of heart muscle damage occurs during the reperfusion phase itself, and no approved drugs specifically target this process. Identifying the molecular drivers of I/R injury is therefore a high clinical priority.
Researchers from Fudan University and Zhejiang University conducted a comprehensive multi-omics investigation to map protein ubiquitination changes in mouse hearts after I/R injury. Ubiquitination is a cellular tagging system that marks proteins for degradation or functional modification. By combining ubiquitinome profiling, single-cell RNA sequencing, and proteomics, the team identified the E3 ubiquitin ligase Hrd1 as significantly upregulated specifically in endothelial cells (ECs) — the cells lining blood vessels — following I/R injury. This elevation was confirmed in both mouse and human cardiac tissue.
The key mechanistic finding was that Hrd1 promotes K33-linked polyubiquitination of ALDH2 (aldehyde dehydrogenase 2), a mitochondrial enzyme with well-established cardioprotective properties. This ubiquitination prevents ALDH2 from assembling into its active tetrameric form, impairing its function and triggering endothelial dysfunction via disruption of the NO/cGMP/PKG signaling pathway — a critical regulator of vascular tone and cell survival.
Genetic deletion of Hrd1 in endothelial cells substantially reduced myocardial infarct size, inflammatory cell infiltration, and vascular dysfunction after I/R. Crucially, pharmacological inhibition of Hrd1 replicated these protective effects, establishing therapeutic proof of concept.
These findings open a new avenue for cardioprotection centered on the ubiquitin-proteasome system. However, the study is preclinical, and translation to human therapy will require safety profiling of Hrd1 inhibitors and validation in larger animal models and clinical trials.
Key Findings
- Hrd1 E3 ubiquitin ligase is upregulated in cardiac endothelial cells after ischemia-reperfusion injury in mice and humans.
- Hrd1 ubiquitinates ALDH2, blocking its active tetramer formation and impairing its cardioprotective function.
- Endothelial-specific Hrd1 deletion significantly reduced infarct size, inflammation, and vascular dysfunction after I/R.
- Pharmacological Hrd1 inhibition reproduced the cardioprotective effects seen with genetic deletion.
- The protective mechanism operates through the NO/cGMP/PKG vascular signaling pathway.
Methodology
The study used global ubiquitinome profiling combined with single-cell RNA sequencing and proteomics in mouse I/R models. Multiple genetic mouse models were employed including global heterozygous Hrd1 knockout, endothelial-specific Hrd1 knockout (Hrd1f/f; Cdh5Cre), and endothelial-specific Hrd1 overexpression via AAV. Mechanistic interactions between Hrd1 and ALDH2 were confirmed by mass spectrometry and immunoprecipitation.
Study Limitations
This study is preclinical, based entirely on mouse models and human tissue samples, with no clinical trial data in patients. The summary is based on the abstract only, so full methodological details, effect sizes, and safety data for Hrd1 inhibitors cannot be assessed. Long-term effects of Hrd1 inhibition on endothelial homeostasis and other organ systems remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.